{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:05:36Z","timestamp":1790222736743,"version":"4.1.0"},"reference-count":147,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"CFF"},{"name":"NIH","award":["P30DK125013"],"award-info":[{"award-number":["P30DK125013"]}]},{"name":"NIH","award":["R01 DK133523"],"award-info":[{"award-number":["R01 DK133523"]}]},{"name":"NIH","award":["R01DK101402"],"award-info":[{"award-number":["R01DK101402"]}]},{"name":"AAS"},{"DOI":"10.13039\/100000897","name":"CF Foundation","doi-asserted-by":"crossref","award":["P30 DK054759"],"award-info":[{"award-number":["P30 DK054759"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000897","name":"CF Foundation","doi-asserted-by":"crossref","award":["R01 DK115791"],"award-info":[{"award-number":["R01 DK115791"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000897","name":"CF Foundation","doi-asserted-by":"crossref","award":["R01DK119699"],"award-info":[{"award-number":["R01DK119699"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000897","name":"CF Foundation","doi-asserted-by":"crossref","award":["RC2 DK124207"],"award-info":[{"award-number":["RC2 DK124207"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Public Health Service","award":["R01 DK97830"],"award-info":[{"award-number":["R01 DK97830"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:p>Cystic fibrosis (CF) is a recessive disorder arising from mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is expressed in numerous tissues, with high expression in the airways, small and large intestine, pancreatic and hepatobiliary ducts, and male reproductive tract. CFTR loss in these tissues disrupts regulation of salt, bicarbonate, and water balance across their epithelia, resulting in a systemic disorder with progressive organ dysfunction and damage. Pancreatic exocrine damage ultimately manifests as pancreatic exocrine insufficiency that begins as early as infancy. Pancreatic remodeling accompanies this early damage, during which abnormal glucose tolerance can be observed in toddlers. With increasing age, however, insulin secretion defects progress such that CF-related diabetes (CFRD) occurs in 20% of teens and up to half of adults with CF. The relevance of CFRD is highlighted by its association with increased morbidity, mortality, and patient burden. While clinical research on CFRD has greatly assisted in the care of individuals with CFRD, key knowledge gaps on CFRD pathogenesis remain. Furthermore, the wide use of CFTR modulators to restore CFTR activity is changing the CFRD clinical landscape and the field\u2019s understanding of CFRD pathogenesis. For these reasons, the National Institute of Diabetes and Digestive and Kidney Diseases and the Cystic Fibrosis Foundation sponsored a CFRD Scientific Workshop, 23\u201325 June 2021, to define knowledge gaps and needed research areas. This article describes the findings from this workshop and plots a path for CFRD research that is needed over the next decade.<\/jats:p>","DOI":"10.2337\/dc23-0380","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T10:06:51Z","timestamp":1682935611000},"page":"1112-1123","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":37,"title":["Cystic Fibrosis\u2013Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes"],"prefix":"10.2337","volume":"46","author":[{"given":"Melissa S.","family":"Putman","sequence":"first","affiliation":[{"name":"1Division of Pediatric Endocrinology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"2Diabetes Research Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Norris","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, University of Iowa, Iowa City, IA"},{"name":"4Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Hull","sequence":"additional","affiliation":[{"name":"5Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle, WA"},{"name":"6Research Service, VA Puget Sound Health Care System, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Rickels","sequence":"additional","affiliation":[{"name":"7Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"},{"name":"8Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Sussel","sequence":"additional","affiliation":[{"name":"9Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Blackman","sequence":"additional","affiliation":[{"name":"10Division of Pediatric Endocrinology and Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Chan","sequence":"additional","affiliation":[{"name":"9Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie Larson","family":"Ode","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, University of Iowa, Iowa City, IA"},{"name":"4Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanicia","family":"Daley","sequence":"additional","affiliation":[{"name":"11Division of Endocrinology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"},{"name":"12Children\u2019s Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene A.","family":"Stecenko","sequence":"additional","affiliation":[{"name":"13Division of Pulmonology, Asthma, Cystic Fibrosis, and Sleep, Department of Pediatrics, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Moran","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan J.","family":"Helmick","sequence":"additional","affiliation":[{"name":"15Cystic Fibrosis Foundation, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Cray","sequence":"additional","affiliation":[{"name":"15Cystic Fibrosis Foundation, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"16Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia A.","family":"Stallings","sequence":"additional","affiliation":[{"name":"17Division of Gastroenterology, Hepatology, and Nutrition, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"18Department of Pediatrics, The University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Tuggle","sequence":"additional","affiliation":[{"name":"15Cystic Fibrosis Foundation, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Clancy","sequence":"additional","affiliation":[{"name":"15Cystic Fibrosis Foundation, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Eggerman","sequence":"additional","affiliation":[{"name":"19Division of Diabetes, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"4Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA"},{"name":"20Department of Anatomy and Cell Biology, University of Iowa Carver College of Medicine, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1724-9868","authenticated-orcid":false,"given":"Andrea","family":"Kelly","sequence":"additional","affiliation":[{"name":"18Department of Pediatrics, The University of Pennsylvania, Philadelphia, PA"},{"name":"21Division of Endocrinology and Diabetes, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"2023052319012770000_B1","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"2023052319012770000_B2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0022-3476(05)80032-0","article-title":"Pancreatic endocrine function in cystic fibrosis","volume":"118","author":"Moran","year":"1991","journal-title":"J Pediatr"},{"key":"2023052319012770000_B3","first-page":"207","article-title":"Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance","volume":"128","author":"Lanng","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2023052319012770000_B4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2023052319012770000_B5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2337\/dc09-1215","article-title":"Diabetes as a determinant of mortality in cystic fibrosis","volume":"33","author":"Chamnan","year":"2010","journal-title":"Diabetes Care"},{"key":"2023052319012770000_B6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes","volume":"146","author":"Marshall","year":"2005","journal-title":"J Pediatr"},{"key":"2023052319012770000_B7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacftor\/ivacaftor in people with cystic fibrosis","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2023052319012770000_B8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2023052319012770000_B9","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2023052319012770000_B10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2023052319012770000_B11","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"2023052319012770000_B12","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"2023052319012770000_B13","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2023052319012770000_B14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"2023052319012770000_B15","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"2023052319012770000_B16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2023052319012770000_B17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N Engl J Med"},{"key":"2023052319012770000_B18","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/nu14061216","article-title":"The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity","volume":"14","author":"Bailey","year":"2022","journal-title":"Nutrients"},{"issue":"R2","key":"2023052319012770000_B19","doi-asserted-by":"crossref","first-page":"R264","DOI":"10.1093\/hmg\/ddab191","article-title":"Human molecular genetics and the long road to treating cystic fibrosis","volume":"30","author":"Harris","year":"2021","journal-title":"Hum Mol Genet"},{"key":"2023052319012770000_B20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ccm.2015.10.005","article-title":"Diagnostic testing in cystic fibrosis","volume":"37","author":"Brewington","year":"2016","journal-title":"Clin Chest Med"},{"key":"2023052319012770000_B21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/ph14090928","article-title":"State of the art on approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators and triple-combination therapy","volume":"14","author":"Meoli","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2023052319012770000_B22","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"2023052319012770000_B23","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1210\/jc.2008-2186","article-title":"Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis","volume":"94","author":"Blackman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2023052319012770000_B24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1172\/JCI129833","article-title":"Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis","volume":"130","author":"Lam","year":"2020","journal-title":"J Clin Invest"},{"key":"2023052319012770000_B25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41436-020-01073-x","article-title":"Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth","volume":"23","author":"Lin","year":"2021","journal-title":"Genet Med"},{"key":"2023052319012770000_B26","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1210\/clinem\/dgz102","article-title":"Genetic modifiers of cystic fibrosis-related diabetes have extensive overlap with type 2 diabetes and related traits","volume":"105","author":"Aksit","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023052319012770000_B27","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1073\/pnas.1914912117","article-title":"Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions","volume":"117","author":"Miller","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023052319012770000_B28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41586-021-03552-w","article-title":"Interpreting type 1 diabetes risk with genetics and single-cell epigenomics","volume":"594","author":"Chiou","year":"2021","journal-title":"Nature"},{"key":"2023052319012770000_B29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pedi.12700","article-title":"\u03b2-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose \u2265155\u2009mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"2023052319012770000_B30","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/diab.43.8.1020","article-title":"Insulin sensitivity in cystic fibrosis","volume":"43","author":"Moran","year":"1994","journal-title":"Diabetes"},{"key":"2023052319012770000_B31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2023052319012770000_B32","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1007\/s00125-020-05210-8","article-title":"A tale of two pancreases: exocrine pathology and endocrine dysfunction","volume":"63","author":"Rickels","year":"2020","journal-title":"Diabetologia"},{"key":"2023052319012770000_B33","doi-asserted-by":"crossref","first-page":"e98240","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI Insight"},{"key":"2023052319012770000_B34","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc17-1387","article-title":"Islet interleukin-1\u03b2 immunoreactivity is an early feature of cystic fibrosis that may contribute to \u03b2-cell failure","volume":"41","author":"Hull","year":"2018","journal-title":"Diabetes Care"},{"key":"2023052319012770000_B35","doi-asserted-by":"crossref","first-page":"17231","DOI":"10.1038\/s41598-017-17404-z","article-title":"Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes","volume":"7","author":"Bogdani","year":"2017","journal-title":"Sci Rep"},{"key":"2023052319012770000_B36","first-page":"742","article-title":"The pancreas in cystic fibrosis: chemical composition and comparative morphology","volume":"10","author":"Kopito","year":"1976","journal-title":"Pediatr Res"},{"key":"2023052319012770000_B37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0046-8177(84)80191-4","article-title":"Endocrine pancreas in cystic fibrosis: an immunohistochemical study","volume":"15","author":"Iannucci","year":"1984","journal-title":"Hum Pathol"},{"key":"2023052319012770000_B38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2337\/db16-0394","article-title":"Reduced \u03b2-cell secretory capacity in pancreatic-insufficient, but not pancreatic-sufficient, cystic fibrosis despite normal glucose tolerance","volume":"66","author":"Sheikh","year":"2017","journal-title":"Diabetes"},{"key":"2023052319012770000_B39","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1210\/jc.2013-4417","article-title":"Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial","volume":"99","author":"Perano","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2023052319012770000_B40","doi-asserted-by":"crossref","first-page":"E851","DOI":"10.1210\/jc.2010-2460","article-title":"Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis\u2014effects of pancreatic enzyme supplementation","volume":"96","author":"Kuo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2023052319012770000_B41","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1210\/clinem\/dgz209","article-title":"In situ analysis reveals that CFTR is expressed in only a small minority of \u03b2-cells in normal adult human pancreas","volume":"105","author":"White","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023052319012770000_B42","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1210\/en.2017-00187","article-title":"CFTR influences beta cell function and insulin secretion through non-cell autonomous exocrine-derived factors","volume":"158","author":"Sun","year":"2017","journal-title":"Endocrinology"},{"key":"2023052319012770000_B43","doi-asserted-by":"crossref","first-page":"e0242749","DOI":"10.1371\/journal.pone.0242749","article-title":"Heterogeneous expression of CFTR in insulin-secreting \u03b2-cells of the normal human islet","volume":"15","author":"Di Fulvio","year":"2020","journal-title":"PLoS One"},{"key":"2023052319012770000_B44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1741-7015-12-87","article-title":"CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells","volume":"12","author":"Edlund","year":"2014","journal-title":"BMC Med"},{"key":"2023052319012770000_B45","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3389\/fphar.2018.01475","article-title":"Animal models in the pathophysiology of cystic fibrosis","volume":"9","author":"Semaniakou","year":"2019","journal-title":"Front Pharmacol"},{"key":"2023052319012770000_B46","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2337\/db05-1647","article-title":"Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury","volume":"55","author":"Stalvey","year":"2006","journal-title":"Diabetes"},{"key":"2023052319012770000_B47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cyto.2008.07.468","article-title":"CFTR mutations impart elevated immune reactivity in a murine model of cystic fibrosis related diabetes","volume":"44","author":"Stalvey","year":"2008","journal-title":"Cytokine"},{"key":"2023052319012770000_B48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/JOE-18-0570","article-title":"Defective exocytosis and processing of insulin in a cystic fibrosis mouse model","volume":"241","author":"Edlund","year":"2019","journal-title":"J Endocrinol"},{"key":"2023052319012770000_B49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41598-017-00098-8","article-title":"CFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells","volume":"7","author":"Edlund","year":"2017","journal-title":"Sci Rep"},{"key":"2023052319012770000_B50","doi-asserted-by":"crossref","first-page":"630654","DOI":"10.3389\/fcell.2021.630654","article-title":"CFTR deficiency affects glucose homeostasis via regulating GLUT4 plasma membrane transportation","volume":"9","author":"Gu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2023052319012770000_B51","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1172\/JCI60610","article-title":"Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets","volume":"122","author":"Olivier","year":"2012","journal-title":"J Clin Invest"},{"key":"2023052319012770000_B52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/CS20140059","article-title":"Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass","volume":"128","author":"Uc","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"2023052319012770000_B53","doi-asserted-by":"crossref","first-page":"e123529","DOI":"10.1172\/jci.insight.123529","article-title":"A sheep model of cystic fibrosis generated by CRISPR\/Cas9 disruption of the CFTR gene","volume":"3","author":"Fan","year":"2018","journal-title":"JCI Insight"},{"key":"2023052319012770000_B54","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ajpath.2012.04.024","article-title":"Pancreatic damage in fetal and newborn cystic fibrosis pigs involves the activation of inflammatory and remodeling pathways","volume":"181","author":"Abu-El-Haija","year":"2012","journal-title":"Am J Pathol"},{"key":"2023052319012770000_B55","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ajpath.2017.12.015","article-title":"Pancreatic and islet remodeling in cystic fibrosis transmembrane conductance regulator (CFTR) knockout ferrets","volume":"188","author":"Rotti","year":"2018","journal-title":"Am J Pathol"},{"key":"2023052319012770000_B56","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.ajpath.2014.01.035","article-title":"Gastrointestinal pathology in juvenile and adult CFTR-knockout ferrets","volume":"184","author":"Sun","year":"2014","journal-title":"Am J Pathol"},{"key":"2023052319012770000_B57","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1210\/en.2015-1935","article-title":"A transient metabolic recovery from early life glucose intolerance in cystic fibrosis ferrets occurs during pancreatic remodeling","volume":"157","author":"Yi","year":"2016","journal-title":"Endocrinology"},{"key":"2023052319012770000_B58","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jcf.2021.04.010","article-title":"Lack of CFTR alters the ferret pancreatic ductal epithelial secretome and cellular proteome: implications for exocrine\/endocrine signaling","volume":"21","author":"Rotti","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B59","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41598-018-37192-4","article-title":"Highly efficient transgenesis in ferrets using CRISPR\/Cas9-mediated homology-independent insertion at the ROSA26 locus","volume":"9","author":"Yu","year":"2019","journal-title":"Sci Rep"},{"key":"2023052319012770000_B60","doi-asserted-by":"crossref","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"key":"2023052319012770000_B61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-pathol-022420-105133","article-title":"Animal models and their role in understanding the pathophysiology of cystic fibrosis-associated gastrointestinal lesions","volume":"16","author":"Gibson-Corley","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"2023052319012770000_B62","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1089\/hum.2022.036","article-title":"Recombinant adeno-associated virus-mediated editing of the G551D cystic fibrosis transmembrane conductance regulator mutation in ferret airway basal cells","volume":"33","author":"Yan","year":"2022","journal-title":"Hum Gene Ther"},{"key":"2023052319012770000_B63","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.arres.2022.100040","article-title":"Oxidative stress and impaired insulin secretion in cystic fibrosis pig pancreas","volume":"5","author":"O\u2019Malley","year":"2022","journal-title":"Adv Redox Res"},{"key":"2023052319012770000_B64","doi-asserted-by":"crossref","first-page":"e112578","DOI":"10.1371\/journal.pone.0112578","article-title":"High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study","volume":"9","author":"Scheuing","year":"2014","journal-title":"PLoS One"},{"key":"2023052319012770000_B65","doi-asserted-by":"crossref","first-page":"e81545","DOI":"10.1371\/journal.pone.0081545","article-title":"Diabetes in cystic fibrosis: multicenter screening results based on current guidelines","volume":"8","author":"Scheuing","year":"2013","journal-title":"PLoS One"},{"key":"2023052319012770000_B66","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s00125-021-05423-5","article-title":"Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis","volume":"64","author":"Bonhoure","year":"2021","journal-title":"Diabetologia"},{"key":"2023052319012770000_B67","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","article-title":"Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline","volume":"17","author":"Chan","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1399-5448.2009.00632.x","article-title":"Oral glucose tolerance testing in children with cystic fibrosis","volume":"11","author":"Ode","year":"2010","journal-title":"Pediatr Diabetes"},{"key":"2023052319012770000_B69","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.numecd.2020.07.044","article-title":"Abnormal glucose tolerance in a pediatric cystic fibrosis cohort: trends in clinical outcomes and associated factors in the preceding years","volume":"31","author":"Nguyen","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2023052319012770000_B70","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jcf.2020.11.022","article-title":"Influence of pre-diabetic and pancreatic exocrine states on pulmonary and nutritional status in adults with cystic fibrosis","volume":"20","author":"Potter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B71","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1164\/rccm.201512-2518OC","article-title":"Abnormal glucose tolerance in infants and young children with cystic fibrosis","volume":"194","author":"Yi","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2023052319012770000_B72","volume-title":"Patient Registry 2020 Annual Data Report","author":"Cystic Fibrosis Foundation","year":"2021"},{"key":"2023052319012770000_B73","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jpeds.2012.08.040","article-title":"Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis","volume":"162","author":"Yen","year":"2013","journal-title":"J Pediatr"},{"key":"2023052319012770000_B74","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"2023052319012770000_B75","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"2023052319012770000_B76","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"2023052319012770000_B77","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"key":"2023052319012770000_B78","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jcf.2019.01.002","article-title":"Visceral adipose tissue is associated with poor diet quality and higher fasting glucose in adults with cystic fibrosis","volume":"18","author":"Bellissimo","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B79","volume-title":"Guideline: Sugars Intake for Adults and Children","author":"World Health Organization","year":"2015"},{"key":"2023052319012770000_B80","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1161\/CIR.0000000000000439","article-title":"Added sugars and cardiovascular disease risk in children: a scientific statement from the American Heart Association","volume":"135","author":"Vos","year":"2017","journal-title":"Circulation"},{"key":"2023052319012770000_B81","volume-title":"2015\u20132020 Dietary Guidelines for Americans","author":"U.S. Department of Health and Human Services and U.S. Department of Agriculture","year":"2015","edition":"8th ed."},{"key":"2023052319012770000_B82","doi-asserted-by":"crossref","first-page":"e0194127","DOI":"10.1371\/journal.pone.0194127","article-title":"Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses","volume":"13","author":"Bellou","year":"2018","journal-title":"PLoS One"},{"key":"2023052319012770000_B83","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis-related diabetes","volume":"107","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2023052319012770000_B84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B85","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome","volume":"19","author":"Olesen","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"2023052319012770000_B87","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Ddata from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B88","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B89","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B90","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"2023052319012770000_B91","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B92","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cmet.2016.08.020","article-title":"Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes","volume":"24","author":"Segerstolpe","year":"2016","journal-title":"Cell Metab"},{"key":"2023052319012770000_B93","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cels.2016.08.011","article-title":"A single-cell transcriptomic map of the human and mouse pancreas reveals inter- and intra-cell population structure","volume":"3","author":"Baron","year":"2016","journal-title":"Cell Syst"},{"key":"2023052319012770000_B94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B95","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcf.2006.03.009","article-title":"Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis","volume":"6","author":"Brennan","year":"2007","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B96","doi-asserted-by":"crossref","first-page":"L43","DOI":"10.1152\/ajplung.00224.2013","article-title":"Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes","volume":"306","author":"Hunt","year":"2014","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2023052319012770000_B97","doi-asserted-by":"crossref","first-page":"37955","DOI":"10.1038\/srep37955","article-title":"Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H+ secretion","volume":"6","author":"Garnett","year":"2016","journal-title":"Sci Rep"},{"key":"2023052319012770000_B98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcf.2015.04.002","article-title":"Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair","volume":"15","author":"Bilodeau","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B99","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1001\/jama.2020.6940","article-title":"Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial","volume":"323","author":"Laffel","year":"2020","journal-title":"JAMA"},{"key":"2023052319012770000_B100","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.2337\/dc14-0303","article-title":"Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry","volume":"37","author":"Wong","year":"2014","journal-title":"Diabetes Care"},{"key":"2023052319012770000_B101","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/dia.2010.0021","article-title":"Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial","volume":"12","author":"Chase","year":"2010","journal-title":"Diabetes Technol Ther"},{"key":"2023052319012770000_B102","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.13994","article-title":"Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes","volume":"318","author":"Karges","year":"2017","journal-title":"JAMA"},{"key":"2023052319012770000_B103","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2337\/dc21-0172","article-title":"Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes","volume":"44","author":"Brown","year":"2021","journal-title":"Diabetes Care"},{"key":"2023052319012770000_B104","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N Engl J Med"},{"key":"2023052319012770000_B105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/dme.13588","article-title":"Diabetes technology: improving care, improving patient-reported outcomes and preventing complications in young people with type 1 diabetes","volume":"35","author":"Prahalad","year":"2018","journal-title":"Diabet Med"},{"key":"2023052319012770000_B106","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/pedi.12777","article-title":"Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: the pumpkin multicenter randomized controlled trial","volume":"19","author":"Mueller-Godeffroy","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"2023052319012770000_B107","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/1932296818766381","article-title":"Continuous glucose monitoring associated with less diabetes-specific emotional distress and lower A1c among adolescents with type 1 diabetes","volume":"12","author":"Vesco","year":"2018","journal-title":"J Diabetes Sci Technol"},{"key":"2023052319012770000_B108","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ecl.2019.10.004","article-title":"Psychosocial aspects of diabetes technology use: the child and family perspective","volume":"49","author":"Papadakis","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2023052319012770000_B109","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0140-6736(20)32514-9","article-title":"A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial","volume":"397","author":"Bergenstal","year":"2021","journal-title":"Lancet"},{"key":"2023052319012770000_B110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1089\/dia.2020.0388","article-title":"Real-world patient-reported outcomes and glycemic results with initiation of Control-IQ technology","volume":"23","author":"Pinsker","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"2023052319012770000_B111","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/dme.13567","article-title":"Psychosocial impacts of hybrid closed-loop systems in the management of diabetes: a review","volume":"35","author":"Farrington","year":"2018","journal-title":"Diabet Med"},{"key":"2023052319012770000_B112","first-page":"753","article-title":"Perceptions of diabetes technology use in cystic fibrosis-related diabetes management","volume":"23","author":"Marks","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"2023052319012770000_B113","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jcf.2018.05.005","article-title":"Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes","volume":"17","author":"Frost","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B114","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/dia.2021.0354","article-title":"The effect of Control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis-related diabetes","volume":"24","author":"Scully","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2023052319012770000_B115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jcf.2019.08.002","article-title":"Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: a pilot study","volume":"19","author":"Sherwood","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B116","first-page":"100276","article-title":"Obesity in cystic fibrosis","volume":"26","author":"Kutney","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"2023052319012770000_B117","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/pedi.12178","article-title":"ISPAD clinical practice consensus guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents","volume":"15","author":"Moran","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"2023052319012770000_B118","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","article-title":"Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2023052319012770000_B119","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.13544","article-title":"Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial","volume":"21","author":"Geyer","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2023052319012770000_B120","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"2023052319012770000_B121","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa2100165","article-title":"Long-term complications in youth-onset type 2 diabetes","volume":"385","author":"Bjornstad","year":"2021","journal-title":"N Engl J Med"},{"key":"2023052319012770000_B122","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.2337\/dc06-0654","article-title":"Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications","volume":"29","author":"Andersen","year":"2006","journal-title":"Diabetes Care"},{"key":"2023052319012770000_B123","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2337\/dc06-1576","article-title":"Microvascular complications in cystic fibrosis-related diabetes","volume":"30","author":"Schwarzenberg","year":"2007","journal-title":"Diabetes Care"},{"key":"2023052319012770000_B124","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2022.07.010","article-title":"Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening","volume":"22","author":"McColley","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2023052319012770000_B125","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1001\/jama.287.19.2519","article-title":"Ethnic disparities in diabetic complications in an insured population","volume":"287","author":"Karter","year":"2002","journal-title":"JAMA"},{"key":"2023052319012770000_B126","first-page":"51","article-title":"Racial and ethnic disparities in diabetes complications in the northeastern United States: the role of socioeconomic status","volume":"105","author":"Osborn","year":"2013","journal-title":"J Natl Med Assoc"},{"key":"2023052319012770000_B127","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1378\/chest.14-2189","article-title":"Assessing differences in mortality rates and risk factors between hispanic and non-hispanic patients with cystic fibrosis in California","volume":"149","author":"Buu","year":"2016","journal-title":"Chest"},{"key":"2023052319012770000_B128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40615-016-0335-8","article-title":"Racial\/ethnic disparities in diabetes quality of care: the role of healthcare access and socioeconomic status","volume":"5","author":"Canedo","year":"2018","journal-title":"J Racial Ethn Health Disparities"},{"key":"2023052319012770000_B129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11892-020-01369-x","article-title":"Diabetes complications in racial and ethnic minority populations in the USA","volume":"21","author":"Haw","year":"2021","journal-title":"Curr Diab Rep"},{"key":"2023052319012770000_B130","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI34773","article-title":"Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer","volume":"118","author":"Rogers","year":"2008","journal-title":"J Clin Invest"},{"key":"2023052319012770000_B131","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.1163600","article-title":"Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs","volume":"321","author":"Rogers","year":"2008","journal-title":"Science"},{"key":"2023052319012770000_B132","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2353\/ajpath.2010.090849","article-title":"Pathology of gastrointestinal organs in a porcine model of cystic fibrosis","volume":"176","author":"Meyerholz","year":"2010","journal-title":"Am J Pathol"},{"key":"2023052319012770000_B133","doi-asserted-by":"crossref","first-page":"29ra31","DOI":"10.1126\/scitranslmed.3000928","article-title":"Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth","volume":"2","author":"Stoltz","year":"2010","journal-title":"Sci Transl Med"},{"key":"2023052319012770000_B134","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1096\/fba.2021-00043","article-title":"Sheep models of F508del and G542X cystic fibrosis mutations show cellular responses to human therapeutics","volume":"3","author":"Viotti Perisse","year":"2021","journal-title":"FASEB Bioadv"},{"key":"2023052319012770000_B135","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1172\/JCI34599","article-title":"Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets","volume":"118","author":"Sun","year":"2008","journal-title":"J Clin Invest"},{"key":"2023052319012770000_B136","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1165\/rcmb.2013-0261OC","article-title":"Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets","volume":"50","author":"Sun","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2023052319012770000_B137","doi-asserted-by":"crossref","first-page":"627666","DOI":"10.3389\/fgene.2020.627666","article-title":"Production of CFTR-\u0394F508 rabbits","volume":"11","author":"Yang","year":"2021","journal-title":"Front Genet"},{"key":"2023052319012770000_B138","doi-asserted-by":"crossref","first-page":"e139813","DOI":"10.1172\/jci.insight.139813","article-title":"Phenotypes of CF rabbits generated by CRISPR\/Cas9-mediated disruption of the CFTR gene","volume":"6","author":"Xu","year":"2021","journal-title":"JCI Insight"},{"key":"2023052319012770000_B139","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/rccm.202002-0369OC","article-title":"Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTR","volume":"202","author":"Birket","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2023052319012770000_B140","article-title":"Static mucus impairs bacterial clearance and allows chronic infection with Pseudomonas aeruginosa in the cystic fibrosis rat","author":"Henderson","journal-title":"Eur Respir J"},{"key":"2023052319012770000_B141","doi-asserted-by":"crossref","first-page":"e97199","DOI":"10.1172\/jci.insight.97199","article-title":"Development of an airway mucus defect in the cystic fibrosis rat","volume":"3","author":"Birket","year":"2018","journal-title":"JCI Insight"},{"key":"2023052319012770000_B142","doi-asserted-by":"crossref","first-page":"e0188497","DOI":"10.1371\/journal.pone.0188497","article-title":"Reduced bone length, growth plate thickness, bone content, and IGF-I as a model for poor growth in the CFTR-deficient rat","volume":"12","author":"Stalvey","year":"2017","journal-title":"PLoS One"},{"key":"2023052319012770000_B143","doi-asserted-by":"crossref","first-page":"e91253","DOI":"10.1371\/journal.pone.0091253","article-title":"Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats","volume":"9","author":"Tuggle","year":"2014","journal-title":"PLoS One"},{"key":"2023052319012770000_B144","doi-asserted-by":"crossref","first-page":"11828","DOI":"10.1038\/s41598-019-48105-4","article-title":"A BAC transgene expressing human CFTR under control of its regulatory elements rescues Cftr knockout mice","volume":"9","author":"Gawenis","year":"2019","journal-title":"Sci Rep"},{"key":"2023052319012770000_B145","doi-asserted-by":"crossref","first-page":"e0175467","DOI":"10.1371\/journal.pone.0175467","article-title":"Growth deficits in cystic fibrosis mice begin in utero prior to IGF-1 reduction","volume":"12","author":"Darrah","year":"2017","journal-title":"PLoS One"},{"key":"2023052319012770000_B146","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1152\/physrev.1999.79.1.S193","article-title":"Pathophysiology of gene-targeted mouse models for cystic fibrosis","volume":"79","author":"Grubb","year":"1999","journal-title":"Physiol Rev"},{"key":"2023052319012770000_B147","first-page":"G258","article-title":"Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis","volume":"273","author":"Grubb","year":"1997","journal-title":"Am J Physiol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/6\/1112\/704545\/dc230380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/6\/1112\/704545\/dc230380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:04:51Z","timestamp":1684854291000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/46\/6\/1112\/148818\/Cystic-Fibrosis-Related-Diabetes-Workshop-Research"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":147,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,1]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-0380","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}